Lactate Kinetics in Septic Shock

Lactate Kinetics in Patients Treated for Septic Shock

Status

Recruiting

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05349370

Acronym

LKISS

Enrollment

Registered

2022-04-27

Start date

2022-12-28

Completion date

2026-12-31

Last updated

2025-05-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sepsis, Septic Shock

Brief summary

Lactate kinetics will be studied in hospitalized septic patients using a bolus injection of stable isotopically labeled lactate.

Detailed description

Adult septic patients admitted to the Intensive Care Unit (ICU) or Intermediary Medical Unit in Karolinska University Hospital will be recruited within 72 hours from start of symptoms. Other than fulfilling the definition for sepsis-3, patients need to be equipped with an arterial catheter to be eligible for inclusion. After informed consent (from next of kin when applicable) baseline blood samples are drawn from existing catheter and the subject is given a bolus dose of 20umol/kg 13C-labeled lactate in 20 ml isotonic saline. After this a total of 14 blood samples á 2 ml is drawn in the following 120 minutes. All blood samples are centrifuged and stored in -800 C until analysis. After all subjects have been included sampled are thawed and analyzed for content of endogenous and labeled lactate. Through analysis between their relationship the lactate production and consumption can be quantified.

Interventions

OTHERIsotopically labeled lactate

A bolus dose of isotopically labeled lactate is given and blood samples from existing catheters are drawn

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

BASIC_SCIENCE

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Sepsis * Age \>17 years * Arterial catheter * Lactate \> 2 mmol at any time point prior to inclusion

Exclusion criteria

* Mitochondrial defect * Degenerative muscle disease * Terminal liver failure

Design outcomes

Primary

Measure	Time frame	Description
Whole body rate of appearance of lactate	2 hours	The total amount of lactate produced per unit of time

Secondary

Measure	Time frame	Description
Clearance of lactate	2 hours	Amount of plasma that is cleared from lactate per unit of time

Countries

Sweden

Contacts

Primary ContactJonathan Grip, MD, PhD

jonathan.grip@regionstockholm.se+46736230906

Backup ContactOlav Rooyackers, Professor

olav.rooyackers@ki.se

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026